World's Best Scientists 2026 revealed!
Matteo S. Carlino

Matteo S. Carlino

D-Index & Metrics

Medicine

D-Index
83
Citations
59979
World Ranking
15333
National Ranking
511

Overview

Matteo S. Carlino is affiliated with the University of Sydney in Australia. Their research predominantly focuses on medicine with significant contributions to oncology and molecular biology subfields. The scientist's work extensively covers cancer immunotherapy, particularly related to melanoma.

The main areas of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Subfields of research involve:

  • Oncology
  • Molecular Biology
  • Immunology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Matteo S. Carlino's primary topics of investigation span:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Cutaneous Melanoma Detection and Management
  • Melanoma and MAPK Pathways
  • Immunotherapy and Immune Responses
  • Cancer Genomics and Diagnostics
  • Brain Metastases and Treatment

Frequent collaborators include:

  • Georgina V. Long
  • Alexander M. Menzies
  • Richard A. Scolyer
  • Serigne Lo
  • Paolo A. Ascierto

Key journals and venues where Matteo S. Carlino publishes work include:

  • Journal of Clinical Oncology
  • European Journal of Cancer
  • Annals of Oncology
  • Journal for ImmunoTherapy of Cancer
  • Cancer Research

Recent papers authored or co-authored by Matteo S. Carlino are:

  • Immune checkpoint inhibitors in melanoma, 2021, The Lancet
  • Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma, 2022, Zurich Open Repository and Archive (University of Zurich)
  • Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study, 2024, The Lancet
  • Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo, 2020, JAMA Oncology
  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology

Best Publications

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Caroline Robert;Caroline Robert;Caroline Robert;Jacob Schachter;Georgina V. Long;Ana Arance

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

    J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

  • Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

    Daniel Y. Wang;Joe Elie Salem;Joe Elie Salem;Justine V. Cohen;Sunandana Chandra

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

    Jacob Schachter;Antoni Ribas;Georgina V. Long;Ana Arance

  • Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

    Jarushka Naidoo;Xuan Wang;Xuan Wang;Xuan Wang;Kaitlin M. Woo;Kaitlin M. Woo;Tunc Iyriboz;Tunc Iyriboz

  • Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

    Georgina V Long;Reinhard Dummer;Omid Hamid;Thomas F Gajewski

  • Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

    Caroline Robert;Antoni Ribas;Jacob Schachter;Ana Arance

  • Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

    Alexander M. Menzies;Alexander M. Menzies;D. B. Johnson;S. Ramanujam;V. G. Atkinson

  • Immune checkpoint inhibitors in melanoma

    Matteo S Carlino;James Larkin;Georgina V Long

  • Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

    Tuba N. Gide;Camelia Quek;Alexander M. Menzies;Annie T. Tasker

  • Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

    Douglas B. Johnson;Ryan J. Sullivan;Patrick A. Ott;Matteo S. Carlino

  • Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

    Jennifer L. McQuade;Carrie R. Daniel;Kenneth R. Hess;Carmen Mak

  • BRAF inhibitor resistance mechanisms in metastatic melanoma; spectrum and clinical impact.

    Helen Rizos;Alexander M. Menzies;Gulietta M. Pupo;Matteo S. Carlino

  • Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

    Alexander M. Menzies;Lauren E. Haydu;Lydia Visintin;Lydia Visintin;Lydia Visintin;Matteo S. Carlino;Matteo S. Carlino

  • Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Jean-Jacques Grob

  • Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

    Alexander M.M. Eggermont;Michal Kicinski;Christian U. Blank;Mario Mandala

Frequent Co-Authors

Georgina V. Long
Georgina V. Long University of Sydney
Alexander M. Menzies
Alexander M. Menzies University of Sydney
Richard A. Scolyer
Richard A. Scolyer Royal Prince Alfred Hospital
Richard F. Kefford
Richard F. Kefford Macquarie University
Helen Rizos
Helen Rizos Macquarie University
Caroline Robert
Caroline Robert University of Paris-Saclay
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Antoni Ribas
Antoni Ribas University of California, Los Angeles
John F. Thompson
John F. Thompson University of Sydney
Douglas B. Johnson
Douglas B. Johnson Vanderbilt University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in medicine but eager to explore alternative or complementary career pathways, there are several online degree options available. Healthcare administration is a rapidly growing field, and students can fast-track their leadership journey with healthcare administration degree programs offered fully online.

Nursing professionals can advance their clinical expertise through asn to fnp programs, allowing registered nurses to become Family Nurse Practitioners with greater autonomy and responsibility.

For those drawn to wellness, nutrition, and preventive care, earning an online bs in nutrition can open doors to careers in dietetics, health education, or allied health sectors.

It’s crucial to choose accredited programs for quality assurance and better career prospects. Interested in administration roles? Explore which online healthcare administration programs have cahme accreditation? to ensure your degree meets recognized healthcare standards.

Best Scientists Citing Matteo S. Carlino

Trending Scientists